@article{oai:tsukuba.repo.nii.ac.jp:02001668,
 author = {Yokota, Kenji and Uchi, Hiroshi and Uhara, Hisashi and Yoshikawa, Shusuke and Takenouchi, Tatsuya and Inozume, Takashi and Ozawa, Kentaro and Ihn, Hironobu and 藤澤, 康弘 and FUJISAWA, Yasuhiro and Qureshi, Anila and de Pril,  Veerle and Otsuka, Yasushi and Weber, Jeffrey and Yamazaki, Naoya},
 issue = {12},
 journal = {Journal of dermatology},
 month = {Dec},
 note = {The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N = 906). In this Japanese subgroup analysis of CheckMate 238 (n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12- and 18-month recurrence-free survival rates were 56% for nivolumab and 30% for ipilimumab (hazard ratio, 0.66; 97.56% confidence interval, 0.19–2.24; P = 0.4390). No new safety signals were reported for Japanese patients. Results were consistent with those from the CheckMate 238 global population, indicating that nivolumab has the potential to be a treatment option for Japanese patients with resected melanoma who are at high risk of recurrence.},
 pages = {1197--1201},
 title = {Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study},
 volume = {46},
 year = {2019},
 yomi = {フジサワ, ヤスヒロ}
}